ORCHIDEA: A Retrospective Study of Patient Demographics, Clinical Characteristics, and Adjuvant Therapy Patterns in Stage II–III HR+/HER2– Breast Cancer Within Routine Clinical Practice

Cover Page

Cite item

Full Text

Abstract

Patients with stage II–III hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- BC) maintain a persistent risk of recurrence for many years despite comprehensive treatment. Identifying risk factors enables adjuvant hormone therapy intensification and recurrence prevention.

References

  1. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахза довой. Состояние онкологической помощи населению VOPROSY ONKOLOGII = PROBLEMS IN ONCOLOGY. 2025;71(6) 1299 КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ / CLINICAL RESEARCH России в 2023 году. Москва: МНИОИ им. П.А. Герце на — филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2024; 262.-URL: https://oncology-association. ru/wp-content/uploads/2024/06/sop-2023-elektronnaya versiya.pdf. [Ed. by A.D. Kaprin. V.V. Starinskii. A.O. Shakhzadova. Malignant tumors in Russia in 2023 (morbidity and mortality). Moscow: P.A. Herzen Moscow State Medical Research Institute — branch of the Federal State Budgetary Institution ‘NMRC of Radiology’ of the Ministry of Health of Russia. 2024; 262.-URL: https://oncology-association. ru/wp-content/uploads/2024/06/sop-2023-elektronnaya versiya.pdf (In Rus)].
  2. Поддубная И.В., Колядина И.В., Калашников Н.Д., et al. Популяционный «портрет» рака молочной же лезы в России: анализ данных российского реги стра. Современная онкология. 2015; 1: 25–29.-URL: https://modernonco.orscience.ru/1815-1434/article/ view/26989. [Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D. et al. A population-based portrait of breast cancer in Russia: a Cancer Register-based analysis in Russian. Journal of Modern Oncology. 2015; 1: 25–29.-URL: https:// modernonco.orscience.ru/1815-1434/article/view/26989 (In Rus)].
  3. Артамонова Е.В., Коваленко Е.И. Системное ле чение рака молочной железы. “Ре Медиа” Мо сква. 2021; 128(илл.).-ISBN: 978-5-6044975-1-7.- URL: https://expose.gpntbsib.ru/expose/vnp-64b55898/ book/ %D0 %932021-23407976950591. [Artamon ova E.V., Kovalenko E.I. Systemic treatment of breast cancer (2nd edition, revised and enlarged) M.: Re Me dia. 2021; 128(ill.).-ISBN: 978-5-6044975-1-7.-URL: https://expose.gpntbsib.ru/expose/vnp-64b55898/ book/ %D0 %932021-23407976950591 (In Rus)].
  4. Клинические рекомендации. Рак молочной железы. 2021.-URL: https://cr.minzdrav.gov.ru/preview-cr/379_. [Clinical recommendations. Breast cancer. 2021.-URL: https://cr.minzdrav.gov.ru/preview-cr/379_4 (In Rus)].
  5. Pan H., Gray R., Braybrooke J., et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017; 377: 1836–46.-DOI: https:// doi.org/10.1056/NEJMoa170183.
  6. Тюляндин С.А., Артамонова Е.В., Жигулев А.Н., et al. Рак молочной железы. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли. 2024; 14(3s2): 32–81. https://doi.org/10.18027/2224-5057- 2024-14-3s2-1.2-01. [Tyulandin S.A., Artamonova E.V., Zhigulev A.N., et al. Breast cancer. RUSSCO Practical Rec ommendations, Part 1.2. Malignant Tumors. 2024; 14(3s2): 32-81.-DOI: https://doi.org/10.18027/2224-5057-2024- 14-3s2-1.2-01 (In Rus)].
  7. Гордеева О.О. Оценка риска рецидива люминально го HER2-отрицательного рака молочной железы и возможности интенсификации адъювантной гормоно терапии для снижения риска прогрессирования. Фарма тека. 2024; 31(6): 207-211.-DOI: https://doi.org/10.18565/ pharmateca.2024.6.207-211.-URL: https://pharmateca. ru/archive/article/45671. [Gordeeva O.O. Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal ther apy to reduce the risk of progression. Pharmateca. 2024; 31(6): 207-211.-DOI: https://doi.org/10.18565/pharmate ca.2024.6.207-211.-URL: https://pharmateca.ru/archive/ article/45671 (In Rus)].
  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more fre quent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019; 393: 1440–52.-DOI: https:// doi.org/10.1016/S0140-6736(18)33137-4.
  9. Davies C., Pan H., Godwin J., et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen recep tor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805–16.-DOI: https://doi.org/10.1016/ S0140-6736(12)61963-1.
  10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001): 1341–52.-DOI: https://doi.org/10.1016/ S0140-6736(15)61074-1.
  11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised tri als. Lancet Oncol. 2022; 23(3): 382–92.-DOI: https://doi. org/10.1016/S1470-2045(21)00758-0.
  12. Gray R.G., Bradley R., Braybrooke J., et al. Effects of ovar ian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopaus al women in 25 randomized trials. J Clin Oncol. 2023; 41: 503–3.-DOI: https://doi.org/10.1200/JCO.2023.41.16_ suppl.503.
  13. Jhaveri K., Pegram M., Neven P., et al. 292P Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR). Annals of Oncology. 2024. 35:S337-S338.-DOI: https://doi. org/10.1016/j.annonc.2024.08.233.-URL: https://www. annalsofoncology.org/article/S0923-7534(24)01752-6/ fulltext.
  14. Johnston S., Martin M., O’Shaughnessy J., et al. Over all survival with abemaciclib in early breast cancer. Ann Oncol. 2025: S0923-7534(25)04948-8.-DOI: https://doi. org/10.1016/j.annonc.2025.10.005.
  15. Hortobagyi G.N., Lacko A., Sohn J., et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025; 36(2): 149-157.- DOI: https://doi.org/10.1016/j.annonc.2024.10.015.
  16. Crown J., Stroyakovskii D., Yardley D.A., et al. Ad juvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative ear ly breast cancer: 5-year follow-up of NATALEE effica cy outcomes and updated overall survival. ESMO Open. 2025; 10(11): 105858.-DOI: https://doi.org/10.1016/j.es moop.2025.105858.-URL: https://www.esmoopen.com/ article/S2059-7029(25)01727-2/fulltext.
  17. Колядина И.В. Место рибоциклиба в лечении раннего гормонозависимого HER2отрицательного рака молочной железы: 4летние результаты рандомизированного контро лируемого исследования III фазы NATALEE и их пере осмысление для клинической практики. Опухоли жен ской репродуктивной системы. 2025; 21(2): 00–00.-DOI: https://doi.org/10.17650/1994-4098-2025-21-2-47-59. [Kolyadina I.V. The role of ribociclib in the treatment of early hormone receptor-positive HER2 negative breast can cer: 4 year results of the randomized controlled phase 3 tri al NATALEE and their reconsideration for clinical practice. (6) doi: 10.37469/0507-3758-2025-71-6-OF-2493 Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Fe male Reproductive System. 2025; 21(2): 00–00.-DOI: https:// doi.org/10.17650/1994-4098-2025-21-2-47-59 (In Rus)].
  18. Li Q., Jiang M., Liu J., et al. Clinicopathologic fea tures, Adjuvant Treatment Patterns and Clinical Out comes of HR+/HER2- Early Breast Cancer in Chi na. The Breast. 2025; 80: 104101.-DOI: https://doi. org/10.1016/j.breast.2025.104101.
  19. Johnston S.R.D., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020; 38(34): 3987-3998.-DOI: https://doi.org/10.1200/JCO.20.02514.
  20. Slamon D., Lipatov O., Nowecki Z., et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024; 390(12): 1080-1091.-DOI: https://doi.org/10.1056/ NEJMoa2305488.
  21. Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Ribo ciclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016; 375(18): 1738-1748.-DOI: https://doi.org/10.1056/nejmoa1609709.-URL: https:// www.nejm.org/doi/full/10.1056/NEJMoa1609709.
  22. Goetz M.P., Toi M., Campone M., et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017; 35(32): 3638-3646.-DOI: https://doi. org/10.1200/JCO.2017.75.6155.
  23. Артамонова Е.В., Владимирова Л.Ю., Жукова Л.Г., et al. Эффективность алпелисиба в реальной клинической прак тике: данные третьего промежуточного анализа исследо вания Prosperity. Газета RUSSCO. 2024; 4: 15-16.-URL: https://rosoncoweb.ru/newspaper/archive/2024/04/. [Artamonova E.V., Vladimirova L.Yu., Zhukova L.G., et al. Efficacy of alpelisib in real-world clinical practice: results of the third interim analysis of the PROSPERITY trial. RUSSCO Newsletters. 2024; 4: 15-16.-URL: https://rosoncoweb.ru/ newspaper/archive/2024/04/ (In Rus)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Problems in Oncology

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).